TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34036357
Drug: 350 g
Normalized name: ALCOHOL 350 g in 500 mL TOPICAL GEL [C2V LINE CLEAR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 350 g Greek yogurt
Study: 35224756
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of m3, Fn and Ch at follow-up
Study: 34119499
Drug: Prophylactic cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic cefazolin 2 g IV (Group A)
Study: 32779728
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone 200 mg daily for 7 days
Study: 33905902
Drug: Sequential administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sequential administration of 2% lidocaine and 0.5% bupivacaine
Study: 32089456
Drug: Proprotein convertase
Normalized name: Proprotein convertase 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprotein convertase subtilisin kexin type 9 inhibitors
Study: 37440232
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual only
Study: 33559248
Drug: Antibody testing
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody testing
Study: 35068061
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg twice daily + tamsulosin 0.4 mg once daily
Study: 34109243
Drug: Pirfenidone 2403
Normalized name: Pirfenidone
DrugBank: Pirfenidone (DB04951)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pirfenidone 2403 mg/day
Study: 32367867
Drug: Ondansetron 4
Normalized name: ondansetron 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 4 mg (Group O)
Study: 32040523
Drug: Higher number
Normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher number of medications per day
Study: 34930617
Drug: veliparib during
Normalized name: veliparib
DrugBank: Veliparib (DB07232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: veliparib during chemotherapy followed by placebo maintenance (veliparib-combination only)
Study: 37460024
Drug: Subcutaneous immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous immunotherapy (SCIT)
Study: 39448207
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy
Study: 34922302
Drug: Cognitive Behavior
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavior Sex Therapy (CBST)
Study: 32588127
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers
Study: 35690827
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDI)
Study: 35338177
Drug: Milvexian 50
Normalized name: Milvexian
DrugBank: Milvexian (DB16233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milvexian 50 mg daily for 14 days
Study: 38918871
Drug: Abatacept (subcutaneous)
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept (subcutaneous)
Study: 32756078
Drug: Sancai powder
Normalized name: Sanchi
DrugBank: Panax notoginseng root (DB14304)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sancai powder (SC) combined with western medicine
Study: 36221341
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine
Study: 35274092
Drug: Low-dose azathioprine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose azathioprine combined with allopurinol
Study: 34669318
Drug: Prophylactic Magnesium
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic Magnesium supplementation (oral for 5 days before surgery)
Study: 34215673
Drug: 68Ga-satoreotide trizoxetan
Normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 68Ga-satoreotide trizoxetan at a peptide mass of 5-20 µg and 30-45 µg with radioactivity ranges of 40-80, 100-140, or 160-200 MBq
Study: 38850034
Drug: Sildenafil 100
Normalized name: sildenafil 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 100 mg
Study: 36041791
Drug: IgAN patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgAN patients (treatment naive)
Study: 34541479
Drug: ALRV5XR treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ALRV5XR treatment
Study: 35397306
Drug: Myofascial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial therapy
Study: 34265462
Drug: ChAdOx1 nCoV-19
Normalized name: ChAdOx1 nCoV-19
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ChAdOx1 nCoV-19 (1 dose)
Study: 34265462
Drug: mRNA BNT162b2
Normalized name: SARS-CoV-2 vaccine, mRNA BNT162b2 bivalent original & OMICRON (BA.4/.5) 0.3 ML Injection, 12y+ (EUA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA BNT162b2 (1 dose)
Study: 39461861
Drug: Intravenous propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous propofol
Study: 33606918
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg
Study: 616505834
Drug: Fibre-free nutrition
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre-free nutrition solution
Study: 33397443
Drug: LSI +
Normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LSI + pioglitazone (PGZ) 15 mg qd
Study: 33220462
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 500 μg
Study: 33220462
Drug: Bencycloquidium bromide
Normalized name: Potassium Bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bencycloquidium bromide (BCQB) 750 μg
Study: 36282530
Drug: risankizumab 150
Normalized name: RISANKIZUMAB 150MG/ML ON-BODY KIT 2.4ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: risankizumab 150 mg
Study: 32016386
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intravenous zoledronate at 5.5 years (PZ, n = 17)
Study: 33565041
Drug: Intensive residential
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive residential treatment for OCD
Study: 32044750
Drug: Knowledge Translation
Normalized name: CONNECTOR,ENFIT TRANSITIONAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knowledge Translation (KT) intervention including weekly email alerts and social media engagement for 12 weeks
Study: 33749643
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid (0.8 mg/day)
Study: 34324836
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (1Dim group) - 5 × 10^10 viral particles
Study: 34324836
Drug: Intramuscular vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vaccination (2Dim group) - 10 × 10^10 viral particles
Study: 32818475
Drug: Multimodal physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal physical therapy
Study: 32732587
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 4000 IU daily
Study: 33601293
Drug: TMZ or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMZ or oral lomustine (CCNU) 110 mg/m2 (TMZ/CCNU)
Study: 32513289
Drug: Ivermectin 400
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin 400 μg/kg
Study: 34932192
Drug: Novel drug
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel drug candidate for nocturnal polyuria
Study: 35691565
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (OC) use
Study: 38273597
Drug: Secukinumab 75
Normalized name: SECUKINUMAB 75MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secukinumab 75 mg
Study: 36049698
Drug: Hand cream
Normalized name: TETRIX HAND CREAM,TOP
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand cream (control group)
Study: 35167764
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (25,000 IU weekly)
Study: 38695087
Drug: Subcutaneous ICD
Normalized name: ICDMT
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous ICD
Study: 33081758
Drug: Continuing oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuing oxytocin infusion
Study: 32051080
Drug: Low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dopamine adjuvant therapy
Study: 32201442
Drug: Methotrexate 7.5
Normalized name: methotrexate 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5 mg/week for 12 weeks
Study: 32201442
Drug: Pioglitazone 15
Normalized name: pioglitazone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 15 mg tablets once daily for 12 weeks
Study: 32061188
Drug: New drug
Normalized name: varicella zoster immune globulin (Investigational New Drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: New drug
Study: 37173129
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment
Study: 35144924
Drug: Anifrolumab basic
Normalized name: anifrolumab
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab basic regimen (BR, 300 mg)
Study: 34003409
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NCT)
Study: 38253897
Drug: Cochlear Implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear Implant (CI)
Study: 37903483
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg
Study: 32023373
Drug: Traditional threshold
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional threshold treatment (glucose concentration <47 mg/dL)
Study: 33055589
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with cisplatin and docetaxel, followed by concomitant chemoradiation therapy with cisplatin, docetaxel, and 45Gy, plus adjuvant cetuximab.
Study: 32195934
Drug: Zopiclone 7.5
Normalized name: zopiclone 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zopiclone 7.5 mg at bedtime
Study: 36093886
Drug: PEEP of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEEP of 12 cmH2O with hourly ARMs (n=83)
Study: 37705327
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (PPI)
Study: 33156099
Drug: Engerix-B double
Normalized name: Engerix-B
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Engerix-B double dose
Study: 32519208
Drug: Well-being under
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Well-being under treatment
Study: 33176205
Drug: Typhoid Conjugate
Normalized name: Typhoid conjugate vaccine (TCV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typhoid Conjugate Vaccine (TCV) plus control vaccine (inactivated polio vaccine) and MCV-A 28 days later
Study: 39697147
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy
Study: 39732701
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual (TAU)
Study: 36305511
Drug: Scheduled acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scheduled acetaminophen and as-needed opioids (Arm A)
Study: 33234138
Drug: Estradiol therapy
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol therapy for women 15–49 years
Study: 34858175
Drug: Red Ginseng
Normalized name: Red ginseng
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red Ginseng (RG) - 3 g/d for 12 weeks
Study: 33645253
Drug: Hyperglycemic clamp
Normalized name: CLAMP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemic clamp protocol with glucose targets of 200 mg/dL and >450 mg/dL, utilizing a centralized spreadsheet-based algorithm for dextrose infusion rates.
Study: 34448273
Drug: TAC monotherapy
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TAC monotherapy (Tacrolimus only after tapering Mycophenolate mofetil)
Study: 38837237
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave therapy (ESWT)
Study: 35255530
Drug: Esketamine 0
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 0 mg/kg
Study: 35776028
Drug: Midazolam-based total
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam-based total intravenous anesthesia (TIVA)
Study: 32703246
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) 900 mg daily for 6 months
Study: 32144522
Drug: Six doses
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six doses of IV‐TXA combined with three doses of IV‐DXM (total dosage = 40 mg)
Study: 32187170
Drug: Rectal positivity
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal positivity for GC
Study: 32187170
Drug: Rectal positivity
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal positivity for CT
Study: 33661918
Drug: Drug-eluting stent
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-eluting stent
Study: 33544990
Drug: O-R toothbrush
Normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-R toothbrush (Oral-B iO)
Study: 35042948
Drug: Dextroamphetamine (d-amp)
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine (d-amp) 10 or 20 mg
Study: 32747497
Drug: BNP infusion
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP infusion
Study: 35307306
Drug: APPv treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: APPv treatment
Study: 36458325
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg (E14)
Study: 33582692
Drug: Caudal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block with 2 mg/kg Bupivacaine mixed with 0.75 mcg/kg Dexmedetomidine (Group B)
Study: 32600336
Drug: Cooling therapy
Normalized name: MENTHOL 2.8 g in 56 g TOPICAL CREAM [elevate COOLING THERAPY TWIST UP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cooling therapy initiated before reperfusion
Study: 32703340
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose naltrexone 6mg daily
Study: 35473439
Drug: Twice-daily dosing
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily dosing of deferasirox
Study: 32303515
Drug: SAFE plus
Normalized name: ALCOHOL 350 mL in 500 mL TOPICAL GEL [WHITE CELEB SAFE PLUS Gel (ETHANOL)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAFE plus treatment‐as‐usual (TAU)
Study: 36894879
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy
Study: 34151607
Drug: Inpatient isolation
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient isolation treatment for COVID-19 patients
Study: 34250977
Drug: Concomitant administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concomitant administration of CYD-TDV and quadrivalent HPV vaccine
Study: 616739365
Drug: Sonidegib 200
Normalized name: sonidegib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 200 mg daily
Study: 32541215
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral feeding (DOF)
Study: 32827412
Drug: NR-INF-02 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NR-INF-02 at 1000 mg for 84 days
Study: 39548016
Drug: Atorvastatin 40
Normalized name: atorvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 40 mg
Study: 38300408
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg
Study: 33009629
Drug: Etifoxine 150
Normalized name: etifoxine
DrugBank: Etifoxine (DB08986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etifoxine 150 mg/day for 12 weeks
Study: 32669099
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (TXA 1.5 g twice daily starting from 3 days before the operation)
Study: 38468293
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT)
Study: 34006388
Drug: Metformin (Met)
Normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (Met) 500 mg tablets twice daily
Study: 32578066
Drug: Steroid group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid group
Study: 32825817
Drug: Goal-directed lactated
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed lactated Ringer's solution (crystalloid)
Study: 33110042
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and Vitamin D (400 IU of 25-hydroxyvitamin-D and 1,000 mg of calcium per day)
Study: 39082471
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockers (CCBs)
Study: 33784280
Drug: Immediate oral
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate oral feeding (8 hours after management)
Study: 33784280
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral feeding (48 hours after management)
Study: 34586357
Drug: Pain Reprocessing
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain Reprocessing Therapy (PRT)
Study: 34478173
Drug: NGT-G
Normalized name: Nitroglycerin
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGT-G
Study: 32006516
Drug: Monovalent varicella
Normalized name: VARICELLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent varicella vaccine
Study: 35701314
Drug: Comprehensive pharmaceutical
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comprehensive pharmaceutical care intervention added to cardiac rehabilitation program
Study: 39186315
Drug: Rituximab therapy
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab therapy
Study: 38746861
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide
Study: 36271942
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (enalapril)
Study: 36084965
Drug: PolyMem dressing
Normalized name: Polymem Dressing 4x5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: PolyMem dressing (conventional treatment)
Study: 35491539
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple doses of Youkenafil Hydrochloride (up to 200 mg single dose and up to 150 mg multiple doses)
Study: 35896462
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C 1000 mg
Study: 35030255
Drug: Sirolimus monotherapy
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus monotherapy
Study: 34882589
Drug: CoronaVac vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoronaVac vaccine
Study: 34910825
Drug: OFD+ABG+L-PRF
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OFD+ABG+L-PRF
Study: 39038096
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT) alone